logo
Rare Yet Alarming: US Study Maps Syphilitic Uveitis Trends

Rare Yet Alarming: US Study Maps Syphilitic Uveitis Trends

Medscape09-06-2025
Between 2013 and 2024, syphilitic uveitis remained a rare but serious manifestation of syphilis in the United States, predominantly affecting men, older individuals, and patients with concurrent HIV, and frequently resulting in low vision and blindness.
METHODOLOGY:
Researchers analyzed data from a national clinical database to determine the incidence and prevalence of syphilitic uveitis in the United States, as well as the rates of sexually transmitted coinfections and associated ocular complications.
Participants with syphilitic uveitis were identified using diagnostic codes for uveitis and positive treponemal and nontreponemal test for syphilis obtained within 1 month of a diagnosis of uveitis.
Data collection included demographic information and rates of concurrent sexually transmitted infections, including HIV, gonorrhea, and chlamydia; these infections were recorded if diagnosed at the time of, or within 1 month after, a diagnosis of uveitis.
Ocular complications included macular edema and low vision or blindness, identified at the time of a diagnosis of uveitis or within 6 months thereafter.
TAKEAWAY:
The researchers identified 161,317 cases of syphilis and 237 cases of syphilitic uveitis; from 2013 to 2024, the cumulative incidence and prevalence rates of syphilitic uveitis were 0.36 and 0.27 per 100,000 individuals, respectively, with both incidence and prevalence increasing over this period.
Compared with the general population in the same database, patients with syphilitic uveitis were more likely to be men and older.
HIV was the most common concurrent sexually transmitted infection, occurring in 32.49% of cases; gonorrhea and chlamydia occurred less frequently, at 4.22%.
The most common complication was low vision or blindness, occurring predominantly in patients with panuveitis or posterior uveitis.
IN PRACTICE:
'Our findings reinforce the need for ordering syphilis testing at uveitis presentation and the prompt initiation of intravenous antibiotic therapy thereafter to prevent irreversible ocular damage,' the researchers wrote.
SOURCE:
The study was led by Lucy Ruoxi Zhou, of the Drexel University College of Medicine in Philadelphia. It was published online on June 4, 2025, in the American Journal of Ophthalmology .
LIMITATIONS:
The reliance on electronic health record databases may have introduced coding variability and inaccuracies. The requirement for syphilis testing to occur within 1 month after a diagnosis of uveitis potentially excluded patients tested before or on the same day as their diagnosis or those experiencing diagnostic delays longer than 1 month. This study could not assess prescribed treatments and changes in clinical endpoints, including improvement in vision or resolution of macular edema after treatment.
DISCLOSURES:
One author received support from the Hankins and Dracopoulos Uveitis Research Funds.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

This Is What Your Poop Is Trying to Tell You About Your Gut Health
This Is What Your Poop Is Trying to Tell You About Your Gut Health

CNET

time13 minutes ago

  • CNET

This Is What Your Poop Is Trying to Tell You About Your Gut Health

While you may not regularly discuss your bowel movements with friends, it is still important to pay attention to them. After all, how often you poop, what your poop looks like and how long it takes you to poop can tell you a lot about your gut health, according to experts. To help you figure out what is normal versus unhealthy, we reached out to three gastroenterologists about everything you've ever wanted to know about your bowel movements. How often should you poop? You probably have someone in your family (if you're honest, maybe it's you) who's convinced they need to poop every morning. However, a healthy pooping schedule isn't the same for every person. You don't need to panic if you're not one of those people who goes to the bathroom like clockwork after your morning coffee. Dr. Lance Uradomo, an interventional gastroenterologist at City of Hope Orange County, explains, "The term 'regular' generally means that a person's bowel movement frequency is continuing without any change." In fact, the number of times you poop every week could vary dramatically from other people in your household with no cause for concern. Dr. Michael Schopis, gastroenterologist and attending physician at Manhattan Gastroenterology, says, "Normal poop frequency can range quite dramatically depending on the person. Pooping anywhere from every other day up to three to four times per day can be considered regular." As a general rule, Uradomo advises, "Three times a day to three times a week is considered a healthy range." However, the doctor warns, "It's important to recognize your own regular routine so that if the frequency suddenly changes, you can alert your doctor." Is it healthier to poop less or more often? Dr. Natasha Chhabra, a gastroenterologist at Gastroenterology Associates of New Jersey, says how often you poop may be less important than whether you're pooping enough. She explains, "Having adequate BMs [bowel movements] with complete evacuation is a great goal, as having a BM is one way our body rids itself of toxins and waste. Some can have a daily BM and still not feel that they have emptied." In other words, having less frequent but complete bowel movements may be healthier than having frequent small bowel movements. How often you should be pooping may also depend on how difficult it is for you to go number two. According to Schopis, "If it requires lots of straining and pushing to have a bowel movement or it requires you to spend 30 minutes on the toilet, then it's probably better for you to try and poop more often." He says you should introduce lifestyle changes to help induce pooping in this situation. The Mayo Clinic recommends eating high-fiber foods, staying hydrated and exercising as natural ways to prevent constipation. On the other hand, it's possible to poop too often. Schopis says, "If someone is going four to five times per day, it's watery and with significant urgency, then this person is probably pooping too much." The Mayo Clinic notes that everything from stomach viruses and bacterial infections to lactose intolerance may cause you to poop frequently. Antibiotics may also lead to temporary does healthy poop look like? Many doctors use the Bristol stool chart to help evaluate the health of bowel movements. The chart is a form scale, meaning that it rates stool based on factors like size and consistency. Bowel movements are rated from 1 to 7, with 1 being the most firm and 7 being entirely liquid. Bristol stool type 1-2: Rabbit or grape-like droppings that are quite hard and may be difficult to pass. Bristol stool type 3-4: Corn on the cob or sausage bowel movements that are soft and easy to pass. Bristol stool type 5-7: Mushy to liquid bowel movements that may or may not include some solid pieces. As Chhabra explains, "The middle of the chart (Bristol 3-4) describes a healthy BM, which is generally described as sausage or snake-like." Poop in these categories is also solid, while it may be either smooth or have some cracks on the surface. A healthy poop in the Bristol 3-4 categories indicates that someone is getting both enough water and enough fiber in their diet, according to Schopis. He notes that this type of stool is often easiest to pass, while "Bristol stool types 1-2 are often hard, pebbly and hard to pass, indicating constipation." If your poop floats, you could have excessive gas, be eating a diet with high-fat content or have a gastrointestinal tract issue. Your poop should sink more often than not. Color You also want to consider the color of your bowel movements. Uradomo reports that "healthy poop can be brown or even greenish but should never be black or contain blood. This could indicate the presence of cancer or other health problems." If your stool is particularly pale, you may want to talk to your doctor about your liver, pancreas and gallbladder health. Smell According to Mount Sinai Hospital, smell also matters. While poop is never meant to smell pleasant, if it suddenly has a new or particularly foul odor, you could be experiencing a condition like chronic pancreatitis or ulcerative colitis. The good news is that changes to your diet can also produce really stinky stool. So if you just have one seriously bad-smelling BM, it could be from eating or drinking something fermented or consuming a lot of garlic. How long should it take you to poop? It shouldn't take you more than a few minutes to poop. Schopis says, "Ideally, someone should spend 5 minutes or less without any pushing or straining to have a bowel movement." Chhabra agrees, explaining, "Spending more than a few minutes having a BM should raise concern for constipation, particularly if you are straining." Uradomo offers a little more leeway, saying, "It should take a person between 5 and 15 minutes on the toilet to have a bowel movement." He warns that sitting on the toilet for longer than that can "lead to problems such as hemorrhoids, reduced circulation or pelvic floor dysfunction." Dusanpetkovic/Getty Images What are the signs of an unhealthy bowel? There are several key signs that you may have an unhealthy bowel. These include: Pain: Frequent pain while pooping may be a cause for concern. This could mean your stool is too hard or there is a larger GI issue. Blood: Blood in the bowl after you poop may also signal an unhealthy bowel. Uradomo warns, "Blood in the stool can be caused by a relatively minor problem like hemorrhoids, but it may also be an indicator of cancer, bowel disease or major internal bleeding." You should monitor bleeding closely and consult your doctor. Loss of bowel control: If you experience bowel (fecal) incontinence, you may be experiencing weakened rectal or anal muscles. Muscle and nerve damage resulting from childbirth may also affect your ability to control bowel movements. Black stool: Uradomo warns that black or tarry-looking stools can indicate bleeding in the upper gastrointestinal tract. This includes your esophagus, stomach and small intestine. Chronic diarrhea: If you often have diarrhea lasting more than a few days, you may be dealing with irritable bowel syndrome or Crohn's disease. Celiac disease can also cause frequent, pale diarrhea. When to talk to your doctor about your poop Any time you're experiencing painful pooping or the inability to have a bowel movement, it's worth talking to your doctor. The NHS warns that chronic constipation can lead to dangerous fecal impaction, and Healthline recommends seeking medical attention if it's been a full week without a bowel movement. Schopis says, "If you're finding that bowel movements control your life, either due to lack of frequency or going too much," it's a great idea to see a doctor. Black or bloody poop also signals that it's time for a medical evaluation. How to keep your poop healthy Sometimes lifestyle changes are all it takes to create healthier poop habits. For instance, make sure you drink enough water. Dehydration may lead to constipation or make your stool harder to pass. Chhabra also recommends eating fiber daily through whole fruits and vegetables. She says this "helps keep your bowel movements fuller and easier to pass." More specifically, Schopis advises people to aim for 2 to 3 liters of water per day and 25 to 30 grams of fiber per day to achieve healthy, normal bowel movements. Aside from this advice, you may want to consider exercising more to help your bowel run smoothly. The bottom line You don't need to poop every day, but you should track your habits and notice when there is a dramatic change. Symptoms like straining to poop or experiencing chronic diarrhea are signs that it's time to make an appointment with your doctor. In the meantime, eating fiber and drinking a lot of water are easy ways to help yourself to poop regularly.

Johnson & Johnson (JNJ)'s Pasritamig Shows Breakthrough Promise in Prostate Cancer
Johnson & Johnson (JNJ)'s Pasritamig Shows Breakthrough Promise in Prostate Cancer

Yahoo

time25 minutes ago

  • Yahoo

Johnson & Johnson (JNJ)'s Pasritamig Shows Breakthrough Promise in Prostate Cancer

We recently published Johnson & Johnson stands second among the most undervalued stocks. Johnson & Johnson (NYSE:JNJ) is a global healthcare leader with a diverse portfolio across pharmaceuticals, medical devices, and consumer health. Its Innovative Medicine division focuses on treatments for complex diseases, while MedTech develops minimally invasive solutions in cardiovascular, orthopedic, surgical, and vision care. In June 2025, Johnson & Johnson (NYSE:JNJ) reported promising Phase 1 results for pasritamig (JNJ-78278343), a first-in-class bispecific T-cell-engaging antibody for metastatic castration-resistant prostate cancer (mCRPC). The drug targets KLK2, a prostate cancer-specific biomarker, and showed early antitumor activity with low treatment-related side effects, indicating potential for safe outpatient use. Pixabay/Public Domain Other notable advances include a supplemental FDA application for STELARA to treat pediatric Crohn's disease, and early Phase 1b data showing encouraging responses from bleximenib—a menin inhibitor—combined with venetoclax and azacitidine for genetically defined acute myeloid leukemia (AML). In vision care, the company launched the first daily disposable multifocal toric contact lens for astigmatism: ACUVUE OASYS MAX 1-Day MULTIFOCAL. Strategically, Johnson & Johnson (NYSE:JNJ) plans to invest $55 billion over four years to expand U.S.-based manufacturing and R&D, aligning with efforts to boost domestic production and supply chain resilience. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Increasing Fundings and Investments, Advanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Growth
Increasing Fundings and Investments, Advanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Growth

Yahoo

time41 minutes ago

  • Yahoo

Increasing Fundings and Investments, Advanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Growth

The global cancer diagnostics market, valued at USD 23.84 billion in 2024, is forecasted to grow at an 11.5% CAGR, reaching USD 70.80 billion by 2034. Key drivers include rising cancer cases, early detection initiatives, and technological advances like AI and liquid biopsies. The robust market includes leaders like Roche, Thermo Fisher, and expanding regions such as North America. Cancer Diagnostics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Cancer Diagnostics Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)" report has been added to global cancer diagnostics market was valued at USD 23.84 Billion in 2024, driven by the rising prevalence of cancer and increasing awareness and early detection initiatives across the globe. The market is anticipated to grow at a CAGR of 11.50% during the forecast period of 2025-2034, with the values likely to reach USD 70.80 Billion by 2034 . Cancer diagnostics involves identifying cancer early to improve treatment outcomes. It typically starts with a clinical evaluation, including physical exams and medical history reviews. Diagnostic tests like imaging (X-rays, CT scans, MRIs, PET scans) detect abnormalities, while blood tests identify cancer markers. Biopsies, where tissue samples are examined under a microscope, confirm malignancy and provide detailed information about the tumour. Advanced methods, such as molecular testing, identify genetic mutations to guide personalised treatments. Screening programmes, like mammograms and colonoscopies, help detect cancer in its early stages. Accurate diagnostics are essential for effective treatment planning and monitoring of disease Diagnostics Market Growth Drivers Rising Merger and Acquisition Activities to Accelerate Market GrowthIncreasing demand for specialised cancer diagnostics and expanding healthcare access in emerging regions are major drivers of growth in the market. For instance, in December 2024, Metropolis Healthcare Limited announced its acquisition of Core Diagnostics, based in Delhi NCR, for USD 29.62 million. This acquisition aims to strengthen Metropolis' cancer testing services and enhance its footprint across Northern and Eastern India. With Core Diagnostics' extensive oncology portfolio and its established network of 200 cities, this move will drive market expansion and enhance diagnostic capabilities. The deal is set to propel Metropolis into a leading position, stimulating market growth in the forecast period by offering advanced cancer diagnostics to a wider Fundings and Investments to Meet Rising Cancer Diagnostics Market DemandGrowing investments in innovative cancer therapies and advancements in radiotherapy are key drivers for the expanding market. For instance, in November 2024, ARC Innovation, part of Sheba Medical Center, secured USD 5.1 million in funding for Starget Pharma, a startup developing targeted radioligand therapies for precise cancer diagnosis and treatment. With funding from the Cancer Focus fund, supported by MD Anderson Cancer Center, Starget Pharma plans to conduct clinical trials on cancers such as sarcomas and melanoma. This breakthrough in cancer diagnostics and treatment will likely enhance the efficacy of therapies and offer new diagnostic tools, positioning this technology to significantly impact the global market in the forecast Diagnostics Market TrendsAdvanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Market GrowthThe market is experiencing the rapid adoption of liquid biopsy technologies, which enable the detection of genetic mutations and biomarkers through blood samples. These non-invasive diagnostic tools are revolutionizing cancer detection by offering early diagnosis and real-time monitoring of treatment response. Liquid biopsy's increased accuracy and reduced patient discomfort are contributing to its growing popularity, particularly in precision oncology. As healthcare systems focus on improving early cancer detection, this technology's market demand is expected to rise significantly. Furthermore, advancements in molecular biology and bioinformatics will further boost its integration into clinical practice, expanding its market of Advanced Technologies to Impact the Cancer Diagnostics Market Value PositivelyArtificial intelligence (AI) and machine learning (ML) are playing a pivotal role in transforming the global cancer diagnostics market. AI-powered diagnostic tools enhance the accuracy of medical imaging, enabling early-stage cancer identification through pattern recognition and predictive analytics. These technologies not only improve diagnostic precision but also streamline workflow efficiencies, reduce human errors, and enhance treatment outcomes. With substantial investments being poured into AI in healthcare, the demand for AI-driven diagnostic solutions is growing. As the technology continues to evolve, its integration into cancer diagnostics will significantly increase market growth, driving future market value and development in the healthcare Partnerships Poised to Drive Cancer Diagnostics Market GrowthThe growing demand for precise and personalised cancer diagnostics is driving strategic collaborations in the field. For instance, in August 2024, Hitachi High-Tech Corporation and Gencurix, Inc. formed a partnership to develop cancer molecular diagnostics. By combining Hitachi's expertise in in vitro diagnostics and digital technologies with Gencurix's proficiency in biomarker discovery, the two companies aim to create advanced testing services. After a successful feasibility study, both companies are now set to commercialise these services in Japan. This collaboration will likely enhance the availability of molecular testing for cancer diagnosis, accelerating the growth of the global cancer diagnostics market by offering cutting-edge, more accurate diagnostic of Next-Generation Sequencing Technology to Increase Cancer Diagnostics Market SizeNext-generation sequencing (NGS) is a breakthrough technology that is rapidly transforming the global cancer diagnostics market. NGS offers high-throughput genomic analysis, enabling comprehensive testing of cancerous tissues to identify genetic mutations and potential therapeutic targets. This technology facilitates early detection of cancer, personalized treatment planning, and monitoring of therapeutic efficacy, contributing to better patient outcomes. The increasing availability of cost-effective NGS platforms and advancements in bioinformatics are driving its integration into clinical oncology practices. As a result, the NGS segment within the cancer diagnostics market is expected to experience substantial growth, adding significant value to the overall market. Key Questions Answered in the Cancer Diagnostics Market What was the global cancer diagnostics market value in 2024? What is the cancer diagnostics market forecast outlook for 2025-2034? What is market segmentation based on technology? How is the market segmented based on application? How is the market segmented based on clinical positioning? What are the major factors aiding the global cancer diagnostics market demand? How has the market performed so far and how is it anticipated to perform in the coming years? What are the market's major drivers, opportunities, and restraints? What are the major cancer diagnostics market trends? Which technology will lead the market segment? Which application will lead the market segment? Which clinical positioning will lead the market segment? Who are the key players involved in the cancer diagnostics market? What is the patent landscape of the market? What are the current unmet needs and challenges in the market? How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics? Key Attributes: Report Attribute Details No. of Pages 400 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $23.84 Billion Forecasted Market Value (USD) by 2034 $70.8 Billion Compound Annual Growth Rate 11.5% Regions Covered Global Supplier Landscape Agilent Technologies, Inc. F. Hoffmann-La Roche AG Thermo Fisher Scientific, Inc. Becton, Dickinson and Company Danaher Corporation GE Healthcare Abbott Siemens Healthineers Bio-Rad Laboratories, Inc. Illumina, Inc. PerkinElmer Inc. QIAGEN Hologic, Inc. Myriad Genetics, Inc. Sysmex Corporation NeoGenomics Laboratories, Inc. Foundation Medicine Grail Guardant Tempus Delfi Diagnotics Exact Sciences Corporation Cancer Diagnostics Market SegmentationMarket Breakup by Technology Blood-based Diagnostics In Vitro Diagnostics Immunoassays Histopathology Others Molecular Diagnostics cfDNA Testing DNA Methylation Analysis Gene Sequencing Polymerase Chain Reaction (PCR) In Situ Hybridization Isothermal Nucleic Acid Amplification Technology (INAAT) Microarrays Spectrometry Others Non-blood-based Diagnostics Imaging CT MRI PET Others Biopsy Comparative Analysis Solid Liquid Others Others Market Breakup by Indication Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Cervical Cancer Blood Cancers (Leukemia and Lymphoma) Skin Cancer (Melanoma) Others Market Breakup by Clinical Positioning Screening Early Detection Treatment Guidance Treatment Response Assessment Market Breakup by Region North America Europe Asia Pacific Latin America Middle East and Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cancer Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store